InnoCare Pharma reports first published clinical evidence of BTK inhibition in systemic lupus erythematosus, with orelabrutinib showing dose‑dependent efficacy, biomarker improvements, and favorable safety in Phase Ib/IIa, supporting ongoing Phase III development.
Written By: Farha Farheen, PharmD
Reviewed By: Pharmacally Editorial Team
InnoCare Pharma has reported publication of positive clinical data for orelabrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor, in the Journal of Autoimmunity, showing encouraging efficacy and a favorable safety profile in patients with systemic lupus erythematosus (SLE). The multicenter Phase Ib/IIa study represents the first published clinical evidence of a BTK inhibitor demonstrating meaningful efficacy in SLE, a disease in which previous agents targeting the same pathway have not achieved similar clinical success.
BTK Inhibition Offers a New Therapeutic Approach
SLE is a chronic autoimmune disease in which the immune system attacks healthy tissues, causing inflammation that can affect the skin, joints, kidneys, blood cells, and other organs. Despite advances in treatment, many patients continue to experience uncontrolled disease or recurrent flares, highlighting the need for additional targeted therapies.
BTK plays a central role in B-cell activation and antibody production, making it an attractive therapeutic target in autoimmune diseases. Orelabrutinib is a highly selective, irreversible BTK inhibitor that achieves sustained target occupancy while minimizing off-target kinase inhibition.
Phase Ib/IIa Trial Demonstrated Dose-Dependent Clinical Responses
The randomized, double-blind, placebo-controlled Phase Ib/IIa trial (NCT04305197) enrolled 60 adults with active SLE across 11 centers in China. Participants received oral orelabrutinib at 50 mg, 80 mg, 100 mg, or placebo once daily for 12 weeks in addition to standard-of-care therapy. The primary objective was to evaluate safety and tolerability, while secondary endpoints assessed clinical response using the SLE Responder Index (SRI)-4 and SRI-6, changes in disease activity, biomarkers, and proteinuria. Fifty-five patients completed the treatment period.
At week 12, SRI-4 response rates increased in a dose-dependent manner, reaching 50%, 62%, and 64% in the 50 mg, 80 mg, and 100 mg groups, respectively, compared with 36% for placebo. The benefit was even more pronounced among patients with higher baseline disease activity (SLEDAI-2K >8), where SRI-4 response rates reached 80%, 83%, and 100%, compared with 0% in the placebo arm. Orelabrutinib treatment was also associated with reductions in proteinuria, anti-double-stranded DNA antibodies (anti-dsDNA), immunoglobulin G (IgG), and immunoglobulin M (IgM), alongside increases in complement C4 levels, indicating improvement in both clinical disease activity and immunologic markers.
Safety Profile Supported Further Clinical Development
The safety profile was consistent with previous experience with orelabrutinib. Most treatment-related adverse events were Grade 1 or 2, with no deaths reported during the study. Treatment-emergent adverse events occurred in 90% of participants overall, while treatment discontinuation due to adverse events was reported in only two patients. Treatment-related serious adverse events occurred in three patients and included liver injury, infectious pneumonia, and abnormal uterine bleeding. Investigators noted that these events resolved with appropriate management, although they emphasized that larger and longer studies are required to better define long-term safety.
Authors Highlight Promise While Acknowledging Study Limitations
The study was led by investigators from Peking University People’s Hospital, with Professor Ru Li and Associate Chief Physician Xue Li serving as co-first authors and Professor Zhanguo Li as the corresponding author. The authors concluded that orelabrutinib was well tolerated and demonstrated promising efficacy signals in patients with active SLE. They also emphasized that the findings should be interpreted cautiously because of the study’s relatively small sample size, short 12-week duration, and enrollment of predominantly patients with mild-to-moderate disease.
Phase III Registrational Study Is Underway
The publication follows InnoCare’s announcement that its larger Phase IIb study met both primary and secondary endpoints, making orelabrutinib the first BTK inhibitor to demonstrate efficacy in a Phase II clinical trial for SLE. Those results were presented at the 2026 European Alliance of Associations for Rheumatology (EULAR) Congress. Patient enrollment is currently ongoing in a registrational Phase III study, which will determine whether these early efficacy findings translate into durable clinical benefit and support future regulatory submissions for patients with SLE.
Reference
Orelabrutinib for systemic lupus erythematosus: A randomised, double-blind, placebo-controlled study
About the Writer
Farha Farheen, PharmD (LinkedIn) is a pharmacy professional with a strong interest in pharmacovigilance and clinical research. She has completed her Doctor of Pharmacy (Pharm.D) along with her internship as a Clinical Pharmacist. She has hands-on experience in adverse drug reaction (ADR) reporting, safety data documentation, and pharmacovigilance workflows, and is proficient in using VigiFlow. She is also a patent holder for an antibacterial formulation enriched with bioactive substances, granted by the German Patent and Trademark Office.